German healthcare and technology group Merck KGaA (MKGAY) is in advanced talks to acquire U.S. cancer and rare disease drugmaker Springworks Therapeutics (SWTX), people familiar with the matter told Reuters’ Sabrina Valle and Patricia Weiss. If the talks are successful, a deal could be signed in the coming weeks, the sources said, though they did not disclose the exact terms being discussed, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics trading halted, volatility trading pause
- SpringWorks should be bought on weakness, says JPMorgan
- TD sees ‘some disappointment’ with lack of SpringWorks Therapeutics M&A news
- SpringWorks Therapeutics Reports Strong 2024 Financial Results
- SpringWorks Therapeutics sees Q4 U.S. OGSIVEO net revenue $61.5M